201 related articles for article (PubMed ID: 32918948)
21. Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α.
Echeverria I; Liu Y; Gabelli SB; Amzel LM
FEBS J; 2015 Sep; 282(18):3528-42. PubMed ID: 26122737
[TBL] [Abstract][Full Text] [Related]
22. Molecular determinants of PI3Kγ-mediated activation downstream of G-protein-coupled receptors (GPCRs).
Vadas O; Dbouk HA; Shymanets A; Perisic O; Burke JE; Abi Saab WF; Khalil BD; Harteneck C; Bresnick AR; Nürnberg B; Backer JM; Williams RL
Proc Natl Acad Sci U S A; 2013 Nov; 110(47):18862-7. PubMed ID: 24190998
[TBL] [Abstract][Full Text] [Related]
23. Structural basis of nSH2 regulation and lipid binding in PI3Kα.
Miller MS; Schmidt-Kittler O; Bolduc DM; Brower ET; Chaves-Moreira D; Allaire M; Kinzler KW; Jennings IG; Thompson PE; Cole PA; Amzel LM; Vogelstein B; Gabelli SB
Oncotarget; 2014 Jul; 5(14):5198-208. PubMed ID: 25105564
[TBL] [Abstract][Full Text] [Related]
24. Insights into the mechanism of the PIK3CA E545K activating mutation using MD simulations.
Leontiadou H; Galdadas I; Athanasiou C; Cournia Z
Sci Rep; 2018 Oct; 8(1):15544. PubMed ID: 30341384
[TBL] [Abstract][Full Text] [Related]
25. Single-Molecule Study Reveals How Receptor and Ras Synergistically Activate PI3Kα and PIP
Buckles TC; Ziemba BP; Masson GR; Williams RL; Falke JJ
Biophys J; 2017 Dec; 113(11):2396-2405. PubMed ID: 29211993
[TBL] [Abstract][Full Text] [Related]
26. In-silico prediction of potential inhibitors against phosphatidylinositol 3-kinase catalytic subunit alpha involved in head and neck squamous cell carcinomas.
Madhukar G; Subbarao N
J Biomol Struct Dyn; 2022 Jul; 40(10):4697-4712. PubMed ID: 33356909
[TBL] [Abstract][Full Text] [Related]
27. Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies.
Roskoski R
Pharmacol Res; 2021 Jun; 168():105579. PubMed ID: 33774181
[TBL] [Abstract][Full Text] [Related]
28. Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
Tran KB; Kolekar S; Jabed A; Jaynes P; Shih JH; Wang Q; Flanagan JU; Rewcastle GW; Baguley BC; Shepherd PR
BMC Cancer; 2021 Feb; 21(1):136. PubMed ID: 33549048
[TBL] [Abstract][Full Text] [Related]
29. Structural insights into phosphoinositide 3-kinase catalysis and signalling.
Walker EH; Perisic O; Ried C; Stephens L; Williams RL
Nature; 1999 Nov; 402(6759):313-20. PubMed ID: 10580505
[TBL] [Abstract][Full Text] [Related]
30. A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane.
Mandelker D; Gabelli SB; Schmidt-Kittler O; Zhu J; Cheong I; Huang CH; Kinzler KW; Vogelstein B; Amzel LM
Proc Natl Acad Sci U S A; 2009 Oct; 106(40):16996-7001. PubMed ID: 19805105
[TBL] [Abstract][Full Text] [Related]
31. Structural dynamics of the N-terminal SH2 domain of PI3K in its free and CD28-bound states.
Hosoe Y; Miyanoiri Y; Re S; Ochi S; Asahina Y; Kawakami T; Kuroda M; Mizuguchi K; Oda M
FEBS J; 2023 May; 290(9):2366-2378. PubMed ID: 36282120
[TBL] [Abstract][Full Text] [Related]
32. Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.
Zhao L; Vogt PK
Cell Cycle; 2010 Feb; 9(3):596-600. PubMed ID: 20009532
[TBL] [Abstract][Full Text] [Related]
33. Human tumor mutants in the p110alpha subunit of PI3K.
Liu Z; Roberts TM
Cell Cycle; 2006 Apr; 5(7):675-7. PubMed ID: 16627990
[TBL] [Abstract][Full Text] [Related]
34. Capitalizing on tumor genotyping: towards the design of mutation specific inhibitors of phosphoinsitide-3-kinase.
Gabelli SB; Duong-Ly KC; Brower ET; Amzel LM
Adv Enzyme Regul; 2011; 51(1):273-9. PubMed ID: 21035489
[TBL] [Abstract][Full Text] [Related]
35. Disease-related mutations in PI3Kγ disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors.
Rathinaswamy MK; Gaieb Z; Fleming KD; Borsari C; Harris NJ; Moeller BE; Wymann MP; Amaro RE; Burke JE
Elife; 2021 Mar; 10():. PubMed ID: 33661099
[TBL] [Abstract][Full Text] [Related]
36. Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.
Huang CH; Mandelker D; Gabelli SB; Amzel LM
Cell Cycle; 2008 May; 7(9):1151-6. PubMed ID: 18418043
[TBL] [Abstract][Full Text] [Related]
37. Structural insight into substrate specificity and regulatory mechanisms of phosphoinositide 3-kinases.
Djordjevic S; Driscoll PC
Trends Biochem Sci; 2002 Aug; 27(8):426-32. PubMed ID: 12151228
[TBL] [Abstract][Full Text] [Related]
38. Dynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS).
Burke JE; Williams RL
Adv Biol Regul; 2013 Jan; 53(1):97-110. PubMed ID: 23194976
[TBL] [Abstract][Full Text] [Related]
39. A class of highly selective inhibitors bind to an active state of PI3Kγ.
Gangadhara G; Dahl G; Bohnacker T; Rae R; Gunnarsson J; Blaho S; Öster L; Lindmark H; Karabelas K; Pemberton N; Tyrchan C; Mogemark M; Wymann MP; Williams RL; Perry MWD; Papavoine T; Petersen J
Nat Chem Biol; 2019 Apr; 15(4):348-357. PubMed ID: 30718815
[TBL] [Abstract][Full Text] [Related]
40. Engineering of an isolated p110α subunit of PI3Kα permits crystallization and provides a platform for structure-based drug design.
Chen P; Deng YL; Bergqvist S; Falk MD; Liu W; Timofeevski S; Brooun A
Protein Sci; 2014 Oct; 23(10):1332-40. PubMed ID: 25043846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
